BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 22752912)

  • 41. Expression of H5 hemagglutinin vaccine antigen in common duckweed (Lemna minor) protects against H5N1 high pathogenicity avian influenza virus challenge in immunized chickens.
    Bertran K; Thomas C; Guo X; Bublot M; Pritchard N; Regan JT; Cox KM; Gasdaska JR; Dickey LF; Kapczynski DR; Swayne DE
    Vaccine; 2015 Jul; 33(30):3456-62. PubMed ID: 26067184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice.
    Tian X; Landreth S; Lu Y; Pandey K; Zhou Y
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.
    Florek KR; Weinfurter JT; Jegaskanda S; Brewoo JN; Powell TD; Young GR; Das SC; Hatta M; Broman KW; Hungnes O; Dudman SG; Kawaoka Y; Kent SJ; Stinchcomb DT; Osorio JE; Friedrich TC
    J Virol; 2014 Nov; 88(22):13418-28. PubMed ID: 25210172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets.
    Bodewes R; Kreijtz JH; van Amerongen G; Geelhoed-Mieras MM; Verburgh RJ; Heldens JG; Bedwell J; van den Brand JM; Kuiken T; van Baalen CA; Fouchier RA; Osterhaus AD; Rimmelzwaan GF
    J Virol; 2010 Aug; 84(16):7943-52. PubMed ID: 20519384
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
    J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recombinant parainfluenza virus 5 expressing hemagglutinin of influenza A virus H5N1 protected mice against lethal highly pathogenic avian influenza virus H5N1 challenge.
    Li Z; Mooney AJ; Gabbard JD; Gao X; Xu P; Place RJ; Hogan RJ; Tompkins SM; He B
    J Virol; 2013 Jan; 87(1):354-62. PubMed ID: 23077314
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety, Immunogenicity, and Protective Efficacy of an H5N1 Chimeric Cold-Adapted Attenuated Virus Vaccine in a Mouse Model.
    Sun W; Wang Z; Sun Y; Li D; Zhu M; Zhao M; Wang Y; Xu J; Kong Y; Li Y; Feng N; Wang T; Zhao Y; Yang S; Gao Y; Xia X
    Viruses; 2021 Dec; 13(12):. PubMed ID: 34960689
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.
    Park SJ; Kim EH; Pascua PNQ; Kwon HI; Lim GJ; Decano A; Kim SM; Song MK; Shin EC; Choi YK
    J Gen Virol; 2014 Apr; 95(Pt 4):793-798. PubMed ID: 24421115
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    Walz L; Kays SK; Zimmer G; von Messling V
    J Virol; 2018 Sep; 92(17):. PubMed ID: 29925654
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cell culture-derived whole-virus H9N2 vaccine induces high titer antibodies against hemagglutinin and neuraminidase and protects mice from severe lung pathology and weight loss after challenge with a highly virulent H9N2 isolate.
    Wodal W; Falkner FG; Kerschbaum A; Gaiswinkler C; Fritz R; Kiermayr S; Portsmouth D; Savidis-Dacho H; Coulibaly S; Piskernik C; Hohenadl C; Howard MK; Kistner O; Barrett PN; Kreil TR
    Vaccine; 2012 Jun; 30(31):4625-31. PubMed ID: 22580355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a dual-protective live attenuated vaccine against H5N1 and H9N2 avian influenza viruses by modifying the NS1 gene.
    Choi EH; Song MS; Park SJ; Pascua PN; Baek YH; Kwon HI; Kim EH; Kim S; Jang HK; Poo H; Kim CJ; Choi YK
    Arch Virol; 2015 Jul; 160(7):1729-40. PubMed ID: 25959557
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
    Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
    PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intranasal immunization of recombinant Lactococcus lactis induces protection against H5N1 virus in ferrets.
    Lei H; Peng X; Ouyang J; Zhao D; Jiao H; Shu H; Ge X
    Virus Res; 2015 Jan; 196():56-9. PubMed ID: 25445345
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Site-Specific Glycan-Masking/Unmasking Hemagglutinin Antigen Design to Elicit Broadly Neutralizing and Stem-Binding Antibodies Against Highly Pathogenic Avian Influenza H5N1 Virus Infections.
    Chen TH; Yang YL; Jan JT; Chen CC; Wu SC
    Front Immunol; 2021; 12():692700. PubMed ID: 34335603
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of homologous and heterologous neuraminidase vaccines in chickens against H5N1 highly pathogenic avian influenza.
    Lee YJ; Sung HW; Choi JG; Lee EK; Jeong OM; Kwon YK; Kwon JH; Song CS; Kimd JH
    Avian Dis; 2007 Mar; 51(1 Suppl):476-8. PubMed ID: 17494612
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and pre-clinical evaluation of two LAIV strains against potentially pandemic H2N2 influenza virus.
    Isakova-Sivak I; de Jonge J; Smolonogina T; Rekstin A; van Amerongen G; van Dijken H; Mouthaan J; Roholl P; Kuznetsova V; Doroshenko E; Tsvetnitsky V; Rudenko L
    PLoS One; 2014; 9(7):e102339. PubMed ID: 25058039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production.
    Dong J; Matsuoka Y; Maines TR; Swayne DE; O'Neill E; Davis CT; Van-Hoven N; Balish A; Yu HJ; Katz JM; Klimov A; Cox N; Li DX; Wang Y; Guo YJ; Yang WZ; Donis RO; Shu YL
    Influenza Other Respir Viruses; 2009 Nov; 3(6):287-95. PubMed ID: 19903211
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.
    Pushko P; Tretyakova I; Hidajat R; Sun X; Belser JA; Tumpey TM
    Vaccine; 2018 Jul; 36(29):4346-4353. PubMed ID: 29885769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heterosubtypic protective immunity against widely divergent influenza subtypes induced by fusion protein 4sM2 in BALB/c mice.
    Chowdhury MY; Seo SK; Moon HJ; Talactac MR; Kim JH; Park ME; Son HY; Lee JS; Kim CJ
    Virol J; 2014 Feb; 11():21. PubMed ID: 24502341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.